I n the United States, patients hospitalized with a primary diagnosis of heart failure (HF) have a 30-day all-cause readmission rate of 12% to 27%, [1] [2] [3] [4] resulting in significant cost to the healthcare system and diminished quality of life. Unfortunately, efforts at predicting readmission among patients hospitalized for HF have produced heterogeneous results and generally have not been as successful as those aimed at predicting mortality. 1, 2, [5] [6] [7] Novel methods for characterizing HF patients' risk of hospital readmission are necessary to improve the care of this vulnerable patient population.
Natriuretic peptides, such as B-type natriuretic peptide (BNP), are released from cardiomyocytes in response to pressure or volume-overloaded states and are a marker of HF severity. 8 The use of natriuretic peptides in the diagnosis of acutely decompensated HF is well established. 9-11 Natriuretic peptides have also been shown to predict both mortality and readmission in a variety of settings [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] ; however, the majority of these studies were small, single center, and did not evaluate hospital readmission separate from mortality. Therefore, the aim of the current study was to examine the association between admission, discharge, and percent change in BNP levels from admission to discharge with 30-day hospital readmission in a large, national cohort of patients within the Veterans Affairs (VA) Health Care System.
Methods Patients and BNP Measurements
Using deidentified data in the national VA Health Care System database, we identified all patients discharged from a VA hospital with a primary diagnosis of HF between 2006 and 2009. According to institutional policy, the current study did not require institutional review board approval. Patients were considered to have a comorbid illness (ie, diabetes, hypertension [HTN] , coronary artery disease [CAD] , stroke and chronic obstructive pulmonary disease [COPD]) if they had been treated for the condition in the 2 years preceding the index admission. Baseline laboratory values (sodium, creatinine, and hemoglobin) were defined as the value within the preceding 6 months that was closest to the day of admission. Patients who died within 30 days of admission were excluded from all readmission analyses. We examined 3 different strategies for assessing BNP: admission levels; discharge levels; and the percent change in BNP levels from admission to discharge. Admission BNP was defined as any BNP value measured on or within 3 days before admission. Discharge BNP was defined as any BNP value measured on or within the 2 days before discharge during a hospital stay lasting >2 days. When multiple BNP measurements met criteria for either admission or discharge BNP, the average was taken. Percent change in BNP from admission to discharge was limited to hospital stays that were longer than 2 days and during which both an admission and discharge BNP were measured. Given the infrequent use of NT-proBNP in the VA population, we limited our analyses to BNP testing.
Outcome
The main outcomes for this study were 30-day all-cause readmission, 30-day HF readmission, and 30-day readmission for other causes. We were particularly interested in the differential impact of BNP on HF and non-HF readmission. Readmission data were limited to hospitalizations paid for by the VA (includes some non-VA hospitalizations). Secondary outcomes included inpatient and 30-day all-cause mortality. Thirty-day outcomes were available for 98.4% of patients (n=108 079 of a total of 109 875). For mortality analyses, we included only the first hospitalization for patients admitted multiple times. The primary analysis of the association between BNP and readmission used unique hospitalizations as the unit of analysis. In sensitivity analyses, we included only the first admission per patient.
Statistics
Patient characteristics are reported as meanAESD. Differences in patient characteristics between those who did and did not have a BNP measured were assessed using the Student t test. The unadjusted association between index admission BNP levels (admission BNP, discharge BNP, and percent change in BNP from admission to discharge) and outcomes (30-day allcause readmission, 30-day HF readmission, 30-day readmission for other causes, and inpatient and 30-day mortality)
were assessed using the chi-square test. Logistic regression models were created for each BNP measurement strategy to assess the association of BNP with 30-day HF readmission after adjustment for demographics (age, black race, and gender), year hospitalized, history of diabetes, HTN, CAD, COPD, stroke, and serum sodium, creatinine, and hemoglobin (base clinical model). In sensitivity analyses, we adjusted for clustering of admissions by patient and facility using generalized estimating equations.
We evaluated discrimination and net reclassification for each BNP strategy utilizing the subset of patients with both admission and discharge BNP data available. Results of logistic regression with and without BNP values were compared to determine the impact of BNP on the area under the receiver operating characteristic curve and the net reclassification improvement (NRI). To determine NRI, we created the following classifications for 30-day all-cause, HF, and non-HF readmission rates: very low (all cause <10%, HF <4%, and non-HF <5%), low (all cause 10% to 19%, HF 4% to 7%, and non-HF 5% to 9%), moderate (all cause 20% to 29%, HF 8% to 11%, and non-HF 10% to 14%), and high (all cause ≥30%, HF specific ≥12%, and non-HF ≥15%). We then analyzed the net number of patients correctly reclassified to a higher or lower risk category when admission, discharge, or change in BNP was added to the base clinical model and, from that, calculated the NRI. 28 For multivariate analyses, we created a separate category of missing (indicator variable) for those categorical variables with missing data. For example, history of diabetes was coded as either present, absent, or missing. Missing continuous variables were imputed using the mean value. There were no missing values for age, sex, and year hospitalized. History of diabetes, stroke, HF, COPD, HTN, and CAD was missing in 5.8% of the hospitalizations studied. Race was missing in 8.5% of hospitalizations, and creatinine, hemoglobin, and sodium were missing in 14%, 13%, and 8.7% of hospitalizations, respectively. A P value <0.05 was considered statistically significant. All analyses were performed using SAS statistical software (version 9.0; SAS Institute Inc., Cary, NC).
Results
Between 2006 and 2009, there were 109 875 admissions with a principle diagnosis of HF documented among 67 094 patients across 125 VA hospitals. A measurement of natriuretic peptide was obtained in over half of admissions, and the majority of levels were BNP (n=55 759; 51%), rather than NT-proBNP (n=4137; 3.7%). There were no clinically relevant differences in baseline clinical characteristics (Table 1) or 30-day readmission outcomes (data not shown) among patients with and without BNP testing during their hospitalization.
BNP Level and Readmission
Admission BNP was measured in 53 585 patients (49%), and discharge BNP was measured in 24 326 (22%). A minority of patients (n=7187; 6.5%) had both an admission and discharge BNP measured. Figure 1 shows the distribution of admission BNP values, discharge BNP values, and the percent change in BNP from admission to discharge. Notably, 43% of patients with a discharge BNP had a value ≥1000 ng/L. Mean BNP levels did not differ significantly between those with only an admission BNP or only a discharge BNP measured and those who had both values measured (data not shown).
Admission, discharge, and percent change in BNP were all correlated with 30-day HF readmission and 30-day all-cause readmission ( Figure 2 ). The risk of 30-day HF readmission increased in a linear fashion as both admission and discharge BNP rose from 200 to 1000 ng/L and was over 3 times higher in patients whose discharge BNP was ≥1000 ng/L versus BNP <200 ng/L.
Adjusted Associations and Incremental Discrimination
The association between each BNP measurement strategy and 30-day HF readmission persisted after controlling for variables in the base clinical model ( Figure 3 ). Odds ratios (ORs) for the other variables included in these models are shown in Table 2 . Because of the significant difference in cohort sizes for admission, discharge, and change in BNP, we compared the discrimination and NRI for each measurement strategy in the 7187 patients with both admission and discharge BNP available (Table 3 ). Of the 3 BNP measurement strategies, discharge BNP conferred the greatest increase in discrimination and net reclassification. When the full cohort for discharge BNP (n=24 326) was analyzed, discharge BNP once again improved both discrimination and net reclassification for 30 In contrast to readmission for HF, readmission for other causes was not associated with admission, discharge, or percent change in BNP (Figure 2 ), even after adjustment for the base clinical model (Table 3 ). There was no appreciable change in C-statistic or NRI for 30-day readmissions for causes other than HF when the full cohorts for either discharge or admission BNP were used (data not shown).
Sensitivity Analyses
When we included only the first admission per patient, the overall admission rate was lower, but the association with BNP was not substantially different. In analyses that controlled for clustering of admissions by patient or within hospitals, the confidence intervals (CIs) widened, but the 
Discussion
This large, population-based study of patients hospitalized with a primary diagnosis of HF demonstrated that admission, discharge, and percent change in BNP levels from admission to discharge were all associated with 30-day HF readmission, but not with 30-day readmission for other causes. This association persisted after adjustment for potential confounders. All 3 BNP measurement strategies provided incremental improvement in discrimination and net reclassification when added to usual predictor variables, with discharge BNP having the largest effect size. Patients' whose admission or discharge BNP was ≥1000 ng/L were 2 to 3 times more likely to be readmitted for HF in 30 days, compared to those with admission or discharge BNP levels <200 ng/L. This effect was most notable for discharge BNP. Finally, both admission and discharge BNP were associated with inpatient and 30-day mortality, with higher BNP levels conferring a greater risk of death. using the 0 to 49 category as a reference) and 30-day heart failure (HF) readmission. B, Forest plot of discharge BNP categories (N=24 326; using the 0 to 49 category as a reference) and 30-day HF readmission. C, Forest plot of percent change in BNP from admission to discharge categories (N=7187; using the ≥70% category as a reference) and 30-day HF readmission; BNP, B-type natriuretic peptide; BNP effect is adjusted for the base clinical model (demographics [age, black race, and gender], year hospitalized, history of diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, stroke, and serum sodium, creatinine, and hemoglobin).
Risk-Stratifying Patients for 30-Day HF Readmission
Our data may help clinicians utilize BNP when determining whether a patient hospitalized for HF is ready for discharge. BNP is a strong marker of HF severity and is correlated with other measures of elevated left ventricular filling pressures, such as pulmonary capillary wedge pressure 29 and tissue Doppler recordings. 30 Although several studies have reported results consistent with our findings, most were small or used a combined primary endpoint of either death and HF readmission, 13, [15] [16] [17] 19, 20, 22, 23, 27, 31, 32 or death and all-cause readmission. 12, 14, 18, 21, 26 In contrast, our study included over 50 000 patients and was thus powered to examine each outcome separately. In the present study, patients with a discharge BNP ≥1000 ng/L had a 30-day HF readmission rate of 15%, compared to only 4.1% for those whose discharge BNP was <200 ng/L. Although admission BNP and percent change in BNP from admission to discharge were also associated with 30-day HF readmission, discharge BNP has several advantages. Not surprisingly, discharge BNP had the largest effect size when examining the association of BNP with 30-day HF readmission. Although our data indicate that admission BNP is measured in twice as many patients as discharge BNP, a BNP obtained at the time patients are deemed ready to leave the hospital may aid in discharge planning and will provide the most accurate prognostic information. For example, a discharge BNP ≥1000 ng/L may cause clinicians to reconsider the timing of hospital discharge and/or arrange for earlier, more intensive outpatient follow-up. Discharge BNP values <1000 ng/L, especially if decreased significantly from admission, may reinforce clinicians' impression when patients are otherwise deemed ready for discharge, with progressively lower values providing more reassurance. If widely implemented, this strategy may significantly reduce HF readmissions, because over 10 000 veterans were discharged with a BNP ≥1000 ng/L from 2006 to 2009. The relation between BNP level and mortality is well documented in the literature. 24, 26, [33] [34] [35] Consistent with previous studies, our data show a strong correlation between higher BNP values (admission and discharge) and smaller percent decreases in BNP from admission to discharge and 30-day mortality. The similarity between our mortality findings and those previously reported in the literature suggests that our findings regarding readmission and BNP may also be applicable to populations beyond the VA Health Care System.
HF Readmissions and Hospital Quality Metrics
We chose the primary endpoints of 30-day all-cause-, HF-, and non-HF-related readmission for several reasons. First, 30-day all-cause readmission rate after a hospitalization for HF is 
Limitations
Although this is a large, national study, it has several limitations that should be taken into account when interpreting the results. First, our population was mostly male, which limits the application of our findings to women. Additionally, we did not have measurements of height and weight, which may have improved the predictive value of BNP given its inverse association with adiposity. 39 Lack of echocardiography data precluded discrimination between HF patients with preserved ejection fraction and those with reduced ejection fraction; however, recent data suggest that BNP is associated with mortality and hospitalization even in patients with preserved ejection fraction. 40 Discharge medications and a measure of functional status were also not available; therefore, we could not adjust for evidence-based medical therapy use or NYHA functional class. Similarly, we could not adjust for HF etiology because angiography data were not available. Our data were limited to rehospitalizations paid for by the VA Health Care System; although this includes some non-VA hospitalizations, the true all-cause readmission rate is likely higher than reported. Finally, a relatively small proportion of patients had both an admission and discharge BNP measured during a hospital stay of greater than 2 days, which limited the analysis of percent change in BNP from admission to discharge.
Conclusion
In this study of over 50 000 veterans hospitalized with a primary diagnosis of HF, BNP levels measured during hospitalization were associated with 30-day HF readmission, but not readmission for other causes. Specifically, patients with a discharge BNP ≥1000 ng/L had an unadjusted 30-day HF-specific readmission rate over 3 times as high as patients' whose discharge BNP was ≤200 ng/L (15% vs. 4.1%, respectively). These data may help clinicians identify patients at risk for HF-specific readmission, allowing disease management and transitional care interventions to be targeted to the highest risk population.
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